Transforming medicine

Results of Placing

Interim Results for the Six Months ended 30 June 2020

Acacia Pharma Advances Preparations for US Launch of BARHEMSYS®

Acacia Pharma Assigned US License for BYFAVO™ (remimazolam) by Cosmo Pharmaceuticals NV

Acacia Pharma Announces US FDA Approval of BYFAVO™ (remimazolam) for injection for the Induction and Maintenance of Procedural Sedation

Acacia Pharma Announces Debt for Equity Swap with Cosmo Pharmaceuticals

Alessandro Della Chà Appointed as Director of Acacia Pharma Group plc

Acacia Pharma Announces Brief Extension of FDA Review Period for NDA for BYFAVO™  

Acacia Pharma Announces Changes to its Officers and Board of Directors

Results for the Year ended 31 December 2019

Acacia Pharma Announces US FDA Approval of BARHEMSYS® (amisulpride) for the Treatment and Prevention of Postoperative Nausea and Vomiting (PONV)

Acacia Pharma Wins BEL Small Company of the Year 2019

Acacia Pharma Announces Planned CFO Succession

Acacia Pharma Enters into Strategic In-licensing, Investment and Loan Transaction with Cosmo Pharmaceuticals N.V.

Acacia Pharma Announces New BARHEMSYS® PDUFA Target Date of 26 February 2020

Interim Results for the Six Months ended 30 June 2019

Founder Dr. Julian Gilbert steps down - Michael Bolinder, Chief Commercial Officer, becomes CEO in Planned Succession

Editorial on Positive Data for BARHEMSYS® Treatment of PONV Published in Anesthesia & Analgesia

Acacia Pharma Plans to Resubmit the BARHEMSYS® NDA in Q3 2019

Annual General Meeting Results and Statement

Acacia Pharma’s BARHEMSYS® Significantly Improves Post-operative Nausea & Vomiting (PONV) in Rescue Treatment of Ambulatory Patients

Notice of Annual General Meeting

Acacia Pharma Receives Complete Response Letter from FDA for BARHEMSYS®

Positive Phase 3 BARHEMSYS® Rescue Treatment Data to be Presented at the Annual Congress of Enhanced Recovery and Perioperative Medicine

Results for the year ended 31 December 2018